SLC5A2 and familial pancreatic carcinoma: The only antihyperglycemic agent negatively associated with the subsequent pancreatic cancer diagnosis was the sodium–glucose cotransporter-2 (SGLT-2) inhibitor, with an odds ratio of 0.80 (95% confidence interval: 0.74–0.87 per year of therapy).